Molecules derived from mechanism based drug design
OwnerDorit Arad, Arthur P Bollon +3inventors
InventorsDorit Arad, Arthur P Bollon, David c Young, Bradley W Poland, Andrew S Peek
Life of this patent
Estimating the term…
Abstract
A method for identifying molecules and designing novel pharmaceuticals is disclosed. The disclosed method of novel pharmaceutical design identifies a novel chemical group that triggers a mechanism of action for an identified reaction, thereby avoiding the various structural complexities associated with the application of the structure-based drug design. Additionally, examples of potential therapeutics identified by the mechanism based drug design method are provided.
Claims20
A molecule comprising a minimal quantity of atoms to trigger a desired reaction wherein said molecule is designed by the following steps:
- (a) determining the minimal quantity of atoms to trigger a desired reaction to occur, said minimal quantity of atoms collectively comprise the trigger mechanism for the desired reaction;
- and
- (b) positioning said minimal quantity of atoms on a ligand wherein said molecule can trigger said desired reaction independently from the naturally occuring desired reaction.
A molecule comprising a minimal number of atoms for inhibiting a mechanism of action of a given reaction wherein said molecule is designed by the following steps:
- (a) determining the trigger mechanism of the given reaction;
- and
- (b) positioning said minimal number of atoms on a ligand wherein said ligand comprises an atom that functions as a poor leaving group when said molecule interacts with a reactant of the given reaction, thereby causing said molecule to inhibit the mechanism of action of the given reaction.
4 A molecule of claim 1 wherein said molecule comprises the minimum quantity of atoms to trigger the reaction of metallo protease and has the following basic structure:
- 105
- wherein B can be any basic group;
- R1 and R2 can be any functional group;
- and
- x can be any atom or group that is more electronegative than sp2 carbon.
A system for developing a small molecule wherein said system comprises:
- (a) a method to compare the stabilization energies of a given reaction between a catalytic residue of an enzyme to residues of a substrate to determine the trigger mechanism for the given reaction,
- (b) a minimal amount of atoms comprising said trigger mechanism of the given reaction;
- and
- (c) a ligand wherein said minimal amount of atoms are positioned on said ligand to form said molecule.
A method for determining the trigger mechanism of a given reaction wherein said method uses a matrix involving the steps of:
- (a) performing ab initio calculations on a class of enzymes to compare a reactive residue associated with a catalytic site common to the class of enzymes to a reactive residue with one or more substrates associated with the class of enzymes;
- (b) using the information generated from step (a) and performing further ab initio calculations on a subclass of enzymes by comparing further reactive residues associated with the catalytic site common to the subclass of enzymes with one or more substates associated with the subclass of enzymes;
- (c) using the information generated from step (b) and performing further ab initio calculations on a single enzyme from the subclass of enzymes by comparing all reaction residues associated with the catalytic site of the enzyme with one or more substrates associated with the enzyme;
- and
- (d) using the information generated from step (c) to determine the trigger mechanism for the enzyme.
A method for determining a trigger mechanism for a given reaction comprising the steps of:
- (a) performing ab initio calculations to determine the stability of each potential interaction between each active site residue of an enzyme and a chemical moiety of one or more substrates of said enzyme;
- (b) analyzing the calculated stabilization energies, wherein the most negative energies are the most reactive species and the most positive energies are the least reactive species;
- and
- (c) combining the chemical moieties that were calculated to be the most reactive, or the least reactive, with each corresponding catalytic residue on a compound scaffold.
A method for deteriming the trigger mechanism of a given reaction comprising the steps of
- (a) aligning a protein sequence of an enzyme with other proteins and determining by homology the general class of the enzyme;
- (b) performing biochemical assays to determine the reaction performed by the enzyme,
- (c) performing site-directed mutagenesis of conserved amino acids and determining if the mutated residues act in the reaction mechanism;
- (d) determining the mechanism of catalytic action for the enzyme;
- and
- (e) performing ab initio calculations to determine the stability of each potential interaction between each active site residue of the enzyme and a chemical moiety of one or more substrates of said enzyme.
A method of designing a small molecule that interacts with the active site of a certain enzyme comprising the steps of.
- (a) aligning the protein sequence of the enzyme with other proteins and determining by homology the general class of enzyme;
- (b) performing biochemical assays to determine the reaction performed by the enzyme;
- (c) performing site-directed mutagenesis of conserved amino acids and determining if the mutated residues act in the reaction mechanism;
- (d) determining the mechanism of catalytic action for the enzyme;
- (e) performing ab initio calculations to determine the stability of each potential interaction between each active site residue of the enzyme and a chemical moiety of one or more substrates of said enzyme;
- (f) analyzing the calculated stabilization energies, wherein the most negative energies are the most reactive species and the most positive energies are the least reactive species;
- and
- (g) combining the chemical moieties that were calculated to be the most reactive, or the least reactive, with each corresponding catalytic residue on a compound scaffold.
A molecule comprising a minimal quantity of atoms to inhibit the activation of telomerase wherein said molecule comprises a poor leaving group.
A molecule comprising a minimal quantity of atoms to inhibit the activation of mycothiol s-conjugate amidase wherein said molecule comprises a poor leaving group.
Dependencies are inferred from the claim text.